Mary Ann Liebert, Inc.

Mary Ann Liebert, Inc. is an academic publishing firm established in 1980 by its president, Mary Ann Liebert. The company specializes in publishing peer-reviewed journals, books, and trade magazines focused on subjects like biotechnology, biomedical research, life sciences, clinical medicine, alternative and integrative medicine, surgery, and law. Its main office is located in New Rochelle, New York, USA.

International

English

Media Company

Outlet metrics

Domain Authority

Ranking

Global

#60837

United States

#35196

Business and Consumer Services/Publishing and Printing

#44

Traffic sources

Monthly visitors

Articles

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

3 weeks ago | liebertpub.com | William Richards |Anthony Bossis |Stephen Ross

Information & AuthorsPublished InHistoryPublished online: 30 May 2025Authors’ ContributionsR.R.G.: Conceptualization, methodology, investigation, writing—original draft, visualization, supervision, project administration, funding acquisition. R.J: Conceptualization, methodology, writing—review and editing, funding acquisition. W.A.R: Conceptualization, methodology, investigation, writing—review and editing, supervision. M.W.J: Conceptualization, methodology, software, writing—review and editing.
The Roles and Responsibilities of Scientific Journals in Research Governance: Editorial Policymaking at Nature and Springer Nature (1995–2023) | The CRISPR Journal

1 month ago | liebertpub.com | Philip Campbell |Stuart A. Newman |James F. Keenan |Tay Salimullah

Scientific journals play an important role in establishing and enforcing ethical standards for the publication of scientific research, including in ethically complex domains like human genome editing.1 In this essay, I discuss my experiences in developing and implementing journal and magazine editorial policies that are directly or generally relevant to the ethical and technical integrity of research, especially in the life and biomedical sciences, social sciences, and humanities.
Delivering Specialty Gases for Potential Therapeutic Effect—Ventilator Validation of Safety Is Paramount | Respiratory Care

2 months ago | liebertpub.com | John Davies

Mechanical ventilators are designed to function using 50 pounds per square inch (psi) inputs from 100% medical grade oxygen and medical grade air only. Introducing a different gas into the system (either through a 50 psi input or into the patient circuit) can potentially have a profound effect on the functionality of the ventilator due to differing chemical properties that the particular gas may have.
The Association Between Thyrotropin and Clinically Relevant Depression: A Retrospective Cross-Sectional Study

Mar 13, 2025 | liebertpub.com | Amanda Bakian |Michael Newman
A Roadmap for Implementation of American Association for Respiratory Care Clinical Practice Guidelines

Mar 3, 2025 | liebertpub.com | Lynda T Goodfellow |Candice J. Devlin |Rory S. O’Bryan |Hope Williams

In this month’s issue, Devlin and colleagues1 provide a roadmap for community hospitals desiring to implement evidence-based guidelines in their practice. This multidisciplinary team began a quality improvement project to address the increased tracheostomized patient census during COVID-19. The aim was to implement recommendations based on the 2021 American Association for Respiratory Care (AARC) Clinical Practice Guideline (CPG)2 for care of tracheostomized patients in their acute care setting.
Ventilator Liberation Practices in Pediatric Cardiac Critical Care

Mar 3, 2025 | liebertpub.com | Amy Romer |Candice J. Devlin |Rory S. O’Bryan |Hope Williams

Get full access to this articleView all available purchase options and get full access to this article. References1. Gaies M, Tabbutt S, Schwartz SM, et al. Clinical epidemiology of extubation failure in the pediatric cardiac ICU: a report from the Pediatric Cardiac Critical Care Consortium. Pediatr Crit Care Med. 2015;16(9):837–845. 2. Abu-Sultaneh S, Iyer NP, Fernández A, et al.
HIV-1 DNA Genotypic Drug Resistance Testing Guides Antiretroviral Therapy in Patients with Low-Level Viremia

Jan 14, 2025 | liebertpub.com | Tong Wang |Li Zhong

Information & AuthorsPublished In AIDS Research and Human RetrovirusesHistoryPublished online: 15 January 2025TopicsData AvailabilityThe data collected in this study will be available to external investigators interested in collaboration upon submission and approval of a data analysis plan. Requests for data should be submitted to [email protected]. Authors’ ContributionsT.W., B.C., and L.Z. conceived the idea and supervised this study.
Esophageal Pressure Measurements to Predict Alveolar Recruitment and Overdistension in Patients With ARDS

Jan 10, 2025 | liebertpub.com | Arnaud W Thille

In patients with ARDS, the main objective of ventilatory management is to avoid alveolar collapse at expiration and alveolar overdistention at inspiration.
Choosing the Proper Interface for Positive Airway Pressure Therapy in Subjects With Acute Respiratory Failure

Dec 17, 2024 | liebertpub.com | Ravi Gupta

IntroductionNoninvasive ventilation (NIV) is a major treatment modality in patients with acute respiratory failure (ARF), as well as chronic respiratory failure and sleep-disordered breathing.1–3 Despite significant advances in NIV technology and the experience of medical staffs, the failure rate of NIV in the acute setting remains high, ranging between 18% and 40%.4 The success of NIV therapy depends on the underlying cause of ARF, patient cooperation, and staff experience.
Cardiovascular Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Virologically Suppressed PLWHIV: A Comparative Analysis of CVD Scores

Oct 29, 2024 | liebertpub.com | Arturo Ciccullo

Get full access to this articleView all available purchase options and get full access to this article. References1. McGettrick P, Mallon PWG, Sabin CA. Cardiovascular disease in HIV patients: Recent advances in predicting and managing risk. Expert Rev anti Infect Ther 2020;18(7):677–688;2. Surial B, Chammartin F, Damas J, et al. Swiss HIV Cohort Study. Impact of integrase inhibitors on cardiovascular disease events in people with human immunodeficiency virus starting antiretroviral therapy.